As the Senate considers Dr. Martin Makary’s nomination to lead the Food and Drug Administration, the safety of all Americans — especially women and children — must be a top priority. For far too long, the FDA has been grossly negligent regarding essential safeguards surrounding the abortion-inducing drug mifepristone. Dr. Makary’s initial hearing provided a glimpse into his commitment to data-based approaches to providing the best care for our patients. I’m hopeful that this expected confirmation will stand as a first step to the FDA reprioritizing the health and safety of women and children.
Despite the common refrain that abortion should be a decision “between a woman and her doctor,” doctors are too often left out of the picture by what has become a highly politicized and aggressively pro-abortion FDA. To the detriment of women’s health and safety, the FDA has for too long made women’s health a pawn in abortion politics by promoting drug-induced abortions as safe and recklessly ignoring the necessity of proper medical oversight.
.png)
.png)
